⌘K

Login Start Free

REGENERON PHARMACEUTICALS, INC.|4Mar 15, 4:01 PM ET

VAGELOS P ROY 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed Mar 15, 2022

Insider Transaction Report

Form 4

Period: 2022-03-14

REGENERON PHARMACEUTICALS, INC.REGN

Director

Transactions

Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2022-03-14−75,000→ 0 total
Exercise: $179.13Exp: 2022-12-14→ Common Stock (75,000 underlying)
Tax Payment
Common Stock
2022-03-14$655.29/sh−48,103$31,521,415→ 345,566 total
Exercise/Conversion
Common Stock
2022-03-14$179.13/sh+75,000$13,434,750→ 393,669 total
Gift
Common Stock
2022-01-04−338→ 141,292 total(indirect: by CLAT)

Holdings

Common Stock
(indirect: By Trust)
37,747
Common Stock
(indirect: By Trust)
3,609
Common Stock
(indirect: By 401(k))
2,096

Footnotes (2)

[F1]By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
[F2]The stock option award vests in four equal annual installments, commencing one year after the date of grant.

Documents

1 file

4
edgardoc.xmlPrimary
PRIMARY DOCUMENT